Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:00 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
August 28, 2023 08:00 ET
|
Innovation Pharmaceuticals Inc
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in...
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
August 23, 2023 09:00 ET
|
GRI Bio, Inc.
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
August 09, 2023 08:05 ET
|
Palisade Bio, Inc.
– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 ...
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
August 08, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against noroviruses including GII.4 pandemic strains ...
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
August 03, 2023 13:25 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
Aridis Pharmaceuticals Announces $2 Million Offering
August 02, 2023 08:17 ET
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies...
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
July 26, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
July 12, 2023 08:00 ET
|
Aridis Pharmaceuticals, Inc.
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company...
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
July 05, 2023 08:45 ET
|
Palisade Bio, Inc.
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...